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Abstract
MLL-AF4 Acute Lymphocytic Leukemia has a poor prognosis, and the mechanisms by which
these leukemias develop are not understood despite intensive research based on well-known
concepts and methods. MicroRNAs (miRNAs) are a new class of small noncoding RNAs that
post-transcriptionally regulate expression of target mRNA transcripts. We recently reported that
ectopic expression of miR-128b together with miR-221, two of the miRNAs downregulated in
MLL-AF4 ALL, restores glucocorticoid resistance through downregulation of the MLL-AF4
chimeric fusion proteins MLL-AF4 and AF4-MLL that are generated by chromosomal
translocation t(4;11). Here we report the identification of new mutations in miR-128b in RS4;11
cells, derived from MLL-AF4 ALL patient. One novel mutation significantly reduces the
processing of miR-128b. Finally, this base change occurs in a primary MLL-AF4 ALL sample as
an acquired mutation. These results demonstrate that the novel mutation in miR-128b in MLL-AF4
ALL alters the processing of miR-128b and that the resultant downregulation of mature miR-128b
contributes to gluco-corticoid resistance through the failure to downregulate the fusion oncogenes.
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Introduction
microRNAs (miRNAs) are a recently discovered class of small noncoding RNAs that are
18–24 nucleotides (nt) long that downregulate target genes at a post-transcriptional level.
The majority of miRNA genes are transcribed by RNA polymerase II into long primary (pri)
miRNA transcripts, processed by the nuclear nuclease Drosha into ~60 bp hairpins termed
precursor (pre) miRNAs, and further cleaved in the cytosol by the Dicer nuclease into
mature miRNAs (Fig. 1). Mature miR-NAs are then incorporated into the multiprotein
RNA-induced silencing complex (RISC), exerting post-transcriptional repression of target
mRNAs,1 either by inducing mRNA degradation or blocking mRNA translation or both.2,3
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Each miRNA is thought to have several target mRNAs, and computational predictions
suggest that more than a third of all human genes are targets of miRNAs.4 In animals,
miRNAs control many developmental and physiological processes. For example, abnormal
expression of certain miRNAs leads to developmental arrest in C. elegans.5 In the
hematopoietic system, miR-181a downregulates several phosphatases that regulate the
sensitivity of T cells to antigens, and overexpression of miR-181 in hematopoietic stem/
progenitor cells significantly increases B cell production. Overexpression of miR-150 leads
to a block in B cell formation at the proB to preB cell transition by downregulating c-myb
among other targets.6–9
Many studies show specific alterations in miRNA expression profiles that correlate with
particular human tumor phenotypes.10,11 Downregulation of specific miRNAs in certain
cancers implies that some miRNAs act as tumor suppressors. For example, reduced
expression of let-7 family members, which directly downregulate the expression of Ras and
other proto-oncogenes, occurs in lung cancer. miR-15 and -16, negative regulators of bcl-2,
exhibit reduced expression in B cell chronic lymphocytic leukemia.12,13 On the other hand,
increased expression of miR-17-92 and miR-155 often occurs in B cell lymphomas,14,15
implying that these miRNAs are oncogenes.15,16
The MLL gene is located at 11q23, a site frequently involved in chromosomal translocations
in aggressive human lymphoid and myeloid leukemias. As a result of these chromosomal
translocations a portion of MLL becomes fused with one of more than forty different partner
proteins, yielding a diverse collection of chimeric fusion proteins. MLL rearrangements are
a common genetic alteration found in human leukemia. Of these MLL associated leukemias,
MLL-AF4 acute lymphocytic leukemia (ALL), resulting from a balanced translocation
between MLL and AF4, occurs in approximately 50% of ALL cases in infants, 2% in
children and 5–6% in adults.17
MLL-AF4 ALL is associated with steroid resistance and has a poor prognosis.18
Overexpression of MLL-AF4 in lymphoid cells reduces cell growth and induces resistance
to etoposide-mediated cytotoxicity.19,20 The reciprocal fusion protein, AF4-MLL, may also
have oncogenic activity and may be an important hit for leukemogenesis.21,22 The detailed
roles of these fusion proteins in leukemogenesis are not well understood.
We focused on miR-128b, which together with miR-221 are two miRNAs commonly
downregulated in MLL rearranged ALL compared to other types of ALL. We hypothesized
that these miRNAs normally downregulate several proteins that contribute to leukemia
development. Recently, we show that re-expression of miR-128b sensitizes two MLL-AF4
ALL cell lines to killing by both low and high concentrations of glucocorticoids, and
cooperates with miR-221 in this process23 (Fig. 2). Furthermore miR-128b downregulates
MLL, AF4, as well as both MLL-AF4 and AF4-MLL fusion genes, and miR-221
downregulates CDKN1B, a downstream transcriptional target of MLL and MLL-AF4,18,23
thus explaining the oncogenic effects of downregulating miR-128b and miR-221.
However, we do not understand the mechanism(s) by which expression of these miRNAs is
downregulated in MLL-AF4 cells. Methylation of the miRNA promoters and aberrant
processing of miRNAs have been are suggested to cause such downregulation. In this
extraview, we report the identification of an A13G point mutation in the miR-128b gene in
RS4;11, an MLL-AF4 ALL cell line. This mutation causes a significant block in the
processing of miR-128b and a reduction in the level of the mature miR-128b. The
downregulation of miR-128b caused by the mutation, and the restoration of gluco-corticoid
sensitivity by the overexpression of miR-128b, showed that this acquired mutation might
play a role in the resistance of MLL-AF4 ALL cells to steroid treatment.
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Results
A point mutation in the pri-miR-128b segment of the miR-128b gene in RS4;11 MLL-AF4
cells
In trying to understand why the level of miR-128b and miR-221 might be reduced in MLL-
AF4 ALL patients, we cloned and sequenced the miR-128b and the miR-221 genes from
RS4;11, a cell line derived from an MLL-AF4 ALL patient. Figure 3A shows that the cells
have a single nucleotide change, A13G, located 13 bp from the 3′ end of mature miR-128b.
This base substitution has been reported neither as a polymorphism nor as a mutation
(International HapMap Project, Entrez SNP,25).
The A13G mutation reduces the processing efficiency of pri-miR128b
To identify the molecular effects of the A13G mutation, expression vectors were constructed
encoding a 316 bp segment of either the wild type (miR-128b-Wt) or the mutated allele
(miR-128b-A13G) of a pri-miR-128b gene. The vectors were transfected into 293T cells,
which express a low level of endogenous miR-128b (data not shown). The A13G mutation
greatly reduced the extent of processing of the miR-128b precursor (Fig. 3B). In cells
expressing miR-128b-A13G, the relative densities of the pri-, pre- and mature miR-128b
“bands” were 1.3, 2.7 and 1.0, respectively, while in miR-128b-Wt-expressing cells, these
values were 0, 0.9 and 1.0, respectively. This result suggests that the processing of the
miR-128b precursor is impeded by the A13G mutation. To confirm and extend this
conclusion, we appended a 240bp pri-miR-221 coding sequence to the 5′ side of miR-128b-
Wt or -A13G; thus mature miR-221 serves as an internal control to assess the efficiencies of
processing of the cotranscribed miR-128b-WT and miR-128b-A13G precursors (Fig. 3C top
right). While the expression levels of pre-miR-128b showed no noticeable difference
between cells expressing the wild-type and A13G miR-128b genes, a significantly lower
level of mature miR-128b was detected in cells transfected with the mutant miRNA gene
compared to the wild-type (Fig. 3C left). Normalized to the expression levels of pre- and
mature miR-221, there was a 2-fold reduction in processing of the A13G mutant pri miRNA
to the mature miRNA (when compared to wild type; Fig. 3C bar graph).
To study the effects of the A13G mutation in an MLL-AF4 ALL cell, miR-128-b-Wt and -
A13G genes were transduced into RS4;11 cells by retroviral infection. As shown by
northern blot analysis, cells expressing exogenous miR-128b-Wt exhibited an increased
level of mature miR-128b compared to that of control cells, while cells expressing
exogenous miR-128b-A13G expressed almost the same level of mature miR-128b as control
cells (Fig. 3D). No bands corresponding to unprocessed pri-miR-128b and only faint bands
of pre-miR-128b could be detected in the northern blot analysis (data not shown). These
results were consistent with the results of quantitative PCR measurements of mature
miR-128b: cells transduced by miR-128b-Wt expressed mature miR-128b at a level five-
times that of control cells, whilst cells transduced by miR-128-b-A13G expressed mature
miR-128b at a level only twice that of the endogenous miR-128b (Fig. 3E upper). In
contrast, quantitative PCR measurements of pri-miR-128b, showed a 17-fold increase in the
level of pri-miR-128b in cells expressing miR-128b-A13G compared to the control, but a 5-
fold increased level in cells transduced with miR-128b-Wt (Fig. 3E middle). The PCR
products of both pri-miR-128bs were sequenced to verify the correct sequence (data not
shown). The processing efficiency was calculated by dividing the expression level of mature
miR-128b by that of the pri-miR-128b. The processing efficiency in cells expressing
exogenous miR-128b-A13G was only one-tenth that of cells expressing miR-128b-Wt (Fig.
3E lower).
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We previously reported that mature miR-128b increases DEX induced apoptosis. In Figure
3F, miR-128b-A13G over-expressing RS4;11 cells, which express mature miR-128b at a
level only twice that of control cells, showed an increase in DEX-induced apoptosis over
control cells, but at all DEX concentrations the extent of DEX-induced apoptosis was
significantly lower than in cells expressing miR-128-b-Wt. Taken together, the A13G
mutation reduces the processing of the miR-128b primary transcript into mature miR-128b
RNA, and thus reduces the effectiveness of miR-128b in restoring glucocorticoid sensitivity
to MLL-AF4 cells.
The A13G mutation is found in some primary human MLL-rearranged ALL tumor cells
In work done using samples collected at the Erasmus MC/Sophia Children’s Hospital,
Rotterdam, 18 human primary MLL-rearranged ALL tumor cell samples were screened for
the presence of the A13G mutation in the miR-128b gene. These samples were collected at
the time of diagnosis before chemotherapy, but direct sequence analysis of the PCR product
of the miR-128b gene showed that none contained mutations. In preliminary experiments,
we amplified by PCR the genomic DNA segment of patient No.1 collected at the Dana
Farber Cancer Institue and sequenced individual clones. One of 77 clones harbored the
A13G mutation, suggesting that a small population of the leukemic cells bear the mutation.
To increase the sensitivity of detection of the mutant allele we developed a nested PCR
strategy (Fig. 4A) in which the primary PCR product was digested with the Tsp45I digestion
(Fig. 4B lower left). Restriction enzyme Tsp45I, which is predicted to cleave the normal but
not the A13G mutant allele. Among the six MLL-rearranged ALL primary patient samples
from the Dana Farber Cancer Institute analyzed, together with three normal samples,
patients 1 and 5 yielded a significant amount of undigested DNA after the 2nd Tsp45I
digestion (Fig. 4B upper left). Subsequent DNA sequence analysis revealed that patient 5
indeed contained the A13G mutant allele while patient 1 did not (Fig. 4B right). Other
patient samples yielded no notable amount of undigested DNA after the 2nd Tsp45I
digestion (Fig. 4B lower left).
That no mutant clones were detected in patient 1 by this analysis contradicted our
preliminary sequence analysis that indicated that patient 1 indeed contained the A13G
mutation. To resolve this issue, an examination of the sequence analysis of the 1st PCR
product from patient 1 revealed that the mutant clone had other mutations in the miR-128b
gene that generated a new Tsp45I restriction site. The new restriction site was located inside
the 2nd nested PCR product, indicating that the mutant clone in patient 1 could not be
amplified by the 2nd nested PCR (data not shown). Thus we conclude that the novel A13G
mutation in pri-miR-128b was found in not only RS4;11, but also in two primary samples of
the six MLL-rearranged ALL tumor DNAs tested. Clearly the occurrence of the mutant
allele in a total leukemic population is rare at the time of presentation of the disease (Fig. 4A
right middle). Thus the A13G mutation likely occurred after the initial chromosomal
translocation.
Discussion
Genetic alteration in miRNAs
Recently several studies illustrating mutations and polymorphisms in primary miRNAs have
been published. Calin reported that in 92 chronic lymphocytic leukemia (CLL) patient
sample, 5 mutations were identified; one of them was homozygous, and displayed complete
abolishment of processing of both miR-15 and miR-16. Other groups identified as many as
24 mutations in members of the let-7 family, miR-15, -16, -124 genes in genomes of
variouls cancer cell lines, but concluded that none of them affected the processing of micro
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RNAs. However, they did not analyze miRNA processing quantitatively as we did in this
study. Similarly, Iwai etc., reported many polymorphisms in primary miRNAs from the 96
Japanese healthy individuals, but these have not been assessed yet for functional alterations.
Our observations suggest that some of these polymorphisms might alter the processing of
miRNAs and lead to disease.25–27
We identified the A13G point mutation in the miR-128b gene in RS4;11, a cell line derived
from an MLL-AF4 ALL patient. This novel mutation significantly reduced the processing of
miR-128b both in transiently transfected 293T cells and stably transduced derived from
relapsed or refractory MLL-AF4 ALL RS4;11 cells. The A13G point mutation in the
miR-128b gene is present both in the RS4;11 cell line and in two out of six primary MLL-
rearranged ALL patient samples. Clearly, because the mutation is present in only a small
population of leukemic cells derived from MLL-rearranged leukemia, the mutation cannot
be responsible for the initiation of the disease. miR-128b is significantly downregulated in
primary MLL rearranged tumors, before chemotherapy.10 Since this would lead to
upregulation of expression of both MLL-AF4 and AF4-MLL fusion proteins, selection for
cells with downregulated miR-128b, whether caused by the A13G mutation or otherwise,
could occur early in disease progression. It is likely that there is also selection for this
mutation, or other genetic or epigenetic changes that cause downregulation of miR-128b,
during later stages of leukemogenesis, especially during steroid treatment, since down-
regulation of mature miR-128b causes the tumor to be refractory to dexamethasone
chemotherapy and relapse. Further studies are needed, using cells tumors after
chemotherapy, to better understand the significance of and selection for the A13G mutation
and other mechanisms that cause miR-128b downregulation.
Materials and Methods
Methods for culturing and studying RS4;11 cells were detailed in our previous paper.23
Determination of A13G mutation of pri-miR-128b in primary samples of tumor DNA
In order to reduce the ratio of normal alleles to the mutant alleles, a genomic 394-bp pri-
miR-128b PCR product, generated using Pfx polymerase (Forward primer, 5′-TGT TCT
TAA GGC TAG GGA ACC A-3′; Reverse primer, 5′-CCG GAA TTC CGG CCG TCA
GGC AGT CTT CAG C-3′), was digested with 5 units of Tsp45I overnight at 65°C and
visualized on an agarose gel. The PCR product of normal sequence is digested by TspI45,
which recognizes the sequence, GTSAC, and two small DNA fragments of 246 and 148 bp
were generated (Fig. 4). If the PCR product contains the A13G mutation, however, the
Tsp45I failed to digest it because the recognition site was disturbed by the mutation
(GTSGC), leaving an undigested 394-bp fragment. The 394-bp undigested product was
purified and placed into the 2nd-round semi-nested PCR reaction (Forward primer, 5′-GGT
TGT TTC AAT ATC GTG CTA AAA-3′; Reverse primer, 5′-CCG GAA TTC CGG CCG
TCA GGC AGT CTT CAG C-3′). The PCR conditions were the same as that described for
pri-miR-128b. After checking by agarose gel electrophoresis that the expected 367-bp
fragment was of acceptable quality, the product was digested again with 5 units of Tsp45I
for 3 hrs at 65°C. After purifying the undigested 367-bp DNA, we sequenced the fragment,
which was expected to be enriched for the A13G mutant allele.
Use of human samples
ALL samples were obtained from patients enrolled on Dana Farber Cancer Institue IRB
approved childhood ALL trials between 1995 and 2005 and Erasmus MC-Sophia Children’s
Hospital IRB approved Interfant-study trials between 1999 and 2007. In all cases the studies
were preapproved by the appropriate Institutional Regulatory Board (IRB). Samples were
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taken from bone marrow or peripheral blood and had >80% blasts. Mononuclear cells were
obtained by density centrifugation, and the DNA was obtained by standard methods.
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Figure 1.
Processing machinery of miRNA. miRNA genes are transcribed by RNA polymerase II or
III into long primary (pri) miRNA transcripts, processed by the nuclear nuclease Drosha into
~60 bp hairpins termed precursor (pre) miRNAs, and further cleaved in the cytosol by the
Dicer nuclease into mature miRNAs. Mature miRNAs are then incorporated into the
multiprotein RNA-induced silencing complex (RISC), exerting post-transcriptional
repression of target mRNAs, either by inducing mRNA cleavage, mRNA degradation or
blocking mRNA translation or both.
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Figure 2.
Ectopic expression of miR-128b and miR-221 restores glucocorticoid sensitivity to RS4;11
cells. RS4;11 cells were infected with bicistronic retroviruses encoding GFP as well as a
specific miRNA. Sorted GFP-positive control- (termed MDH), let7b-, miR-221- or
miR-128b-transduced cells are treated (DEX+) or not (DEX−) with 10 μM dexamethasone
for 40 hours, followed by FACS analysis. The percentage of viable cells is determined by
dividing the number of Annexin V(−) GFP (+) cells by the number of total cells analyzed.
Taken from ref. 23.
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Figure 3.
A point mutation in pri-miR-128b in RS4;11 cells blocks the processing of pri-miR-128b to
mature miR-128b. (A) DNA chromatograms illustrating the genomic sequence of miR-128b
DNA from RS 4;11 cells. Nucleotides are indicated by capital letters. +13 indicates the
A13G base substitution. Note that the wt and mutant sequence are both present. The base
substitution is located 13 bp from the 3′ end of mature miR-128b miRNA. (B) Northern blot
analysis of primary, precursor and mature miR-128b expression in 293T cells transiently
transfected by miR-128b-Wt and -A13G. Arrows indicate (top to bottom) primary (pri),
precursor (pre), and mature miR-128b respectively. The relative intensities of each band
were normalized to the mature miR-128b by using Multigage software and are indicated
above each band. (C) Northern blot analysis of precursor and mature miR-221 (left) and
miR-128b (middle) in 293T cells transiently transfected by a vector encoding both miR-221
and miR-128b-Wt or miR-128b A13G. The graph shows the relative intensities of precursor
and mature miR-128b normalized to those of miR-221 using Multigage software (right). (D)
Northern blot analysis of mature miR-128b expression in RS4;11 cells transduced by
miR-128b-Wt, -A13G, and control (C) vector. Expression of 5S RNA is used as the loading
control. The graph shows that the relative intensities of each band normalized to the 5S
loading control using Multigage software. (E) Quantitative PCR for mature miR-128b in
RS4;11 cells transduced by miR-128b-Wt, -A13G and control (upper). The position of
primers that detect both unprocessed and processed pri-miR-128b (middle upper). The
arrows with solid lines and dotted lines indicate the position of the primers for PCR and RT,
respectively. Quantitative PCR for the unprocessed and processed pri-miR-128b in RS4;11
cells transduced by miR-128b-Wt, -A13G, and control vector (middle lower). The
processing efficiency is calculated as the ratio of expression levels of mature and primary
miR-128b (lower). (F) Sorted GFP (+) miR-128b-Wt-, -A13G- or control-transduced cells
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are treated with an increasing concentration of dexamethasone for 40 hrs, followed by FACS
analysis. GFP (+) cells are assessed for viability by Annexin V staining as the same way as
in Figure 2.
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Figure 4.
Detection of the A13G mutant miR-128b allele in a primary MLL-AF4 ALL tumor. (A)
Schematic of the procedure used to enrich the mutant alleles is shown along with the gel
images that are analyzed at each step. After the 1st genomic PCR, the target bands are seen
in all samples. The arrow indicates the expected size of the PCR product. After digestion of
the 1st PCR products by Tsp45I, which cleaves the wild-type but not the A13G mutant
DNA, no bands corresponding to the undigested PCR product, which corresponds to the
mutant allele, are visible in any of these samples. The arrows (top to bottom) indicate the
predicted sizes of DNAs corresponding to the undigested and the two digested products.
After the 2nd semi-nested PCR, all samples show the expected amplified species; the arrow
indicates the expected size of the PCR product. 1–9 indicated patients 1 to 9; a–f, normal
control a, b, c; P, positive control that contains 10% of mutant and 90% wild type DNA. (B)
After the digestion of the 2nd PCR products by Tsp45I, patients 1 and 5 show an undigested
DNA, which corresponds to the mutant allele, as indicated by the upper arrows (upper left).
Other patient samples show no undigested DNA (i.e., wild-type sequence; lower left). The
DNA sequence analysis demonstrated that the PCR product from patient 5, as well as the
positive control (P) show a G base at position 13, that is, the A13G mutation, while patient 1
showed only an A base at this position (right). The arrow indicates the position of A13G
mutation.
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